FDA approves Gilead's Hepsera

The FDA granted marketing approval to GILD for its Hepsera adefovir dipivoxil nucleotide analog to treat chronic hepatitis B virus (HBV) infection in adults. The product, which GILD expects to ship to wholesalers next week, received a positive FDA panel recommendation in August. ...